^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
Published date:
12/03/2021
Excerpt:
CONTRADICTING EVIDENCE: We included 153 adults with relapsed or refractory LBCL treated with CD19-CAR-T (axicabtagene ciloleucel [50%], tisagenlecleucel [32%], and lisocabtagene maraleucel [18%])....TP53 alterations (mutations and/or copy number alterations) were common (37%) and associated with inferior CR and OS rates in univariable and multivariable regression models; the 1-year OS in TP53-altered LBCL was 44% (95% CI, 29 to 67) versus 76% (65 to 89) in wild-type (P = .012).
DOI:
10.1200/JCO.21.02143
Source:
Title:
TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma
Published date:
11/04/2021
Excerpt:
Patients with relapsed/refractory LBCL treated with CD19-CAR-T were included….TP53 genomic alterations were common (28, 37%)….TP53-alterations were also predictive of OS in univariable and multivariable Cox regression (Fig. C-D; 1-year OS in TP53-altered (48% [95% CI 32 – 71]) vs. wild-type (75% [64 – 89]), p = 0.039)....Notably, in TP53-altered LBCL, axicabtagene-ciloleucel therapy was associated with superior OS ...
DOI:
10.1182/blood-2021-145158
Test:
